{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:14Z","timestamp":1767134654309,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":100,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd001719.pub3","type":"reference-entry","created":{"date-parts":[[2011,8,31]],"date-time":"2011-08-31T10:47:01Z","timestamp":1314787621000},"source":"Crossref","is-referenced-by-count":0,"title":["Bromperidol decanoate (depot) for schizophrenia"],"prefix":"10.1002","author":[{"given":"Marianna","family":"Purgato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive E","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,9,7]]},"reference":[{"key":"10.1002\/14651858.CD001719.pub3-BIB1|cit1","series-title":"Annual General Meeting of the British Association for Psychopharmacology. Cambridge, England. July 15-18,1990","article-title":"A comparative trial of bromperidol decanoate and fluphenazine decanoate in chronic schizophrenia","author":"McLaren","year":"1990"},{"key":"10.1002\/14651858.CD001719.pub3-BIB2|cit2","series-title":"8th World Congress of Psychiatry; Athens, Greece","article-title":"Bromperidol decanoate: a comparative study in chronic schizophrenia","author":"McLaren"},{"key":"10.1002\/14651858.CD001719.pub3-BIB3|cit3","first-page":"67","article-title":"Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates","volume":"7","author":"McLaren","year":"1992","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB4|cit4","series-title":"8th World Congress of Psychiatry. Athens, Greece","article-title":"Bromperidol decanoate versus fluphenazine decanoate in schizophrenia","author":"Casacchia"},{"key":"10.1002\/14651858.CD001719.pub3-BIB5|cit5","first-page":"1379","article-title":"Therapeutic evaluation of bromperidol decanoate in schizophrenia - a double-blind comparison vs. fluphenazine decanoate","volume":"114","author":"Rossi","year":"1990","journal-title":"Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali"},{"key":"10.1002\/14651858.CD001719.pub3-BIB6|cit6","first-page":"265","article-title":"Action of bromperidol decanoate in the treatment of negative symptoms of schizophrenia - comparison with haloperidol decanoate","volume":"27","author":"Rossi","year":"1992","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub3-BIB7|cit7","series-title":"8th World Congress of Psychiatry. Athens, Greece","article-title":"Bromperidol decanoate versus placebo in residual schizophrenia","author":"Bellini"},{"key":"10.1002\/14651858.CD001719.pub3-BIB8|cit8","first-page":"187","article-title":"Bromperidol decanoate versus placebo in treating schizophrenia in the residual phase","volume":"6","author":"Smeraldi","year":"1990","journal-title":"New Trends in Experimental and Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD001719.pub3-BIB9|cit9","first-page":"271","article-title":"Efficacia terapeutica e tollerabilita del bromperidolo decanoato in pazienti psicotici gia in trattamento con aloperidolo o clorpromazina","volume":"27","author":"Bernardi","year":"1992","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub3-BIB10|cit10","series-title":"14th CINP Congress. Florence, Italy","article-title":"6-month study of bromperidol decanoate in chronic psychotic patients","author":"Boeykens"},{"key":"10.1002\/14651858.CD001719.pub3-BIB11|cit11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2007-1019585","article-title":"A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients","volume":"14","author":"Brannen","year":"1981","journal-title":"Pharmacopsychiatria"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB12|cit12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000468826","article-title":"Introductory words to the exchange of results on the clinical effects of bromperidol. Results of open and double blind research","volume":"13","author":"Bures","year":"1978","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB13|cit13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000468454","article-title":"Clinical evaluation of bromperidol versus haloperidol in psychotic patients","volume":"15","author":"Denijs","year":"1980","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB14|cit14","first-page":"267","article-title":"Clinical evaluation of sultopride hydrochloride on outpatients with schizophrenia","volume":"23","author":"Fukahori","year":"1995","journal-title":"Japanese Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD001719.pub3-BIB15|cit15","first-page":"233","article-title":"Clinical therapeutic experience with bromperidol - a double blind and open study","volume":"25","author":"Germana","year":"1990","journal-title":"Rivista di Psichiatria"},{"key":"10.1002\/14651858.CD001719.pub3-BIB16|cit16","series-title":"3rd World Congress of Biological Psychiatry. Stockholm, Sweden","article-title":"Maintenance therapy of schizophrenia with a novel depot neuroleptic bromperidol decanoate","author":"Gould"},{"key":"10.1002\/14651858.CD001719.pub3-BIB17|cit17","series-title":"13th CINP Congress. Jerusalem, Israel","article-title":"Relationship between plasma drug concentrations and clinical response after treatment with bromperidol or fluphenazine decanoate","author":"Gould"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB18|cit18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000468827","article-title":"The use of bromperidol in an open study","volume":"13","author":"Hucker","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub3-BIB19|cit19","first-page":"1296","article-title":"The clinical psychopharmacological efficacy of bromperidol for schizophrenia comparison with haloperidol by the single-blind cross-over method","volume":"21","author":"Hyugano","year":"1986","journal-title":"Shinryo to Shinyaku"},{"key":"10.1002\/14651858.CD001719.pub3-BIB20|cit20","first-page":"120","article-title":"A comparison of the clinical effects of bromperidol, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique","volume":"21","author":"Itoh","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB21|cit21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000468825","article-title":"Neuroleptic potency of bromperidol","volume":"13","author":"Kaumeier","year":"1978","journal-title":"International Pharmacopsychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB22|cit22","first-page":"296","article-title":"The clinical efficacy of bromperidol for schizophrenia: comparison with haloperidol by the double-blind method","volume":"12","author":"Kodama","year":"1984","journal-title":"Igaku to Yakugaku"},{"issue":"11","key":"10.1002\/14651858.CD001719.pub3-BIB23|cit23","first-page":"3721","article-title":"The comparative study of bromperidol and clocapramine for schizophrenia by the double-blind method","volume":"61","author":"Kokasa","year":"1984","journal-title":"Rinsho To Kenkyu"},{"issue":"10","key":"10.1002\/14651858.CD001719.pub3-BIB24|cit24","first-page":"1283","article-title":"A double blind comparison of bromperidol and clocapramine on schizophrenia","volume":"13","author":"Kudo","year":"1984","journal-title":"Rinsho Seishin Igaku (Japanese Journal of Clinical Psychiatry)"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB25|cit25","first-page":"51","article-title":"Valutazione dell'efficacia e della tollerabilita del trattamento a lungo termine con bromperidolo decanoato nei disturbi psicotici","volume":"33","author":"Levi Minzi","year":"1992","journal-title":"Minerva Psichiatrica"},{"key":"10.1002\/14651858.CD001719.pub3-BIB26|cit26","first-page":"147","article-title":"Double-blind evaluation of bromperidol versus haloperidol treatment in chronic psychotic patients","volume":"78","author":"Malfroid","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub3-BIB27|cit27","first-page":"187","article-title":"Schizophrenic disorder in active phase: Double-blind study between bromperidol and haloperidol","volume":"16","author":"Mauri","year":"1994","journal-title":"Giornale di Neuropsicofarmacologia"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub3-BIB28|cit28","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/1096-8628(20000612)96:3<422::AID-AJMG35>3.0.CO;2-5","article-title":"No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study","volume":"96","author":"Mihara","year":"2000","journal-title":"American Journal of Medical Genetics"},{"key":"10.1002\/14651858.CD001719.pub3-BIB29|cit29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0165-1781(00)00247-X","article-title":"No relationship between - 141 C Ins\/del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonist in schizophrenic patients: a preliminary study","volume":"1","author":"Mihara","year":"2001","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD001719.pub3-BIB30|cit30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1471-244X-8-95","article-title":"The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)","volume":"8","author":"Hanssens","year":"2008","journal-title":"BMC psychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB31|cit31","unstructured":"Millet B A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients (Schizophrenia Trial of Aripiprazole - STAR) http:\/\/www.clinicaltrials.gov 2005"},{"key":"10.1002\/14651858.CD001719.pub3-BIB32|cit32","first-page":"373-82. Awaits","article-title":"Clinical effects of bromperidol on schizophrenia","volume":"30","author":"Nishizono","year":"1984","journal-title":"Kyushu Shinkei Seishin Igaku Kyushu Neuro-psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub3-BIB33|cit33","first-page":"3349","article-title":"The double-blind comparative study of bromperidol and haloperidol in the treatment of schizophrenic inpatients","volume":"18","author":"Onodera","year":"1984","journal-title":"Kiso to Rinsho"},{"key":"10.1002\/14651858.CD001719.pub3-BIB34|cit34","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00007691-199704000-00008","article-title":"No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite","volume":"19","author":"Otani","year":"1997","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB35|cit35","first-page":"1","article-title":"Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation","volume":"34","author":"Parent","year":"1983","journal-title":"Current Therapeutic Research"},{"key":"10.1002\/14651858.CD001719.pub3-BIB37|cit36","first-page":"96","article-title":"Clinical experiences in an open and a double-blind trial","volume":"78","author":"Poldinger","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub3-BIB36|cit37","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000468306","article-title":"Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol","volume":"12","author":"Poldinger","year":"1977","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB38|cit38","first-page":"1089","article-title":"Therapeutic evaluation of bromperidol in schizophrenia - double-blind comparison with chlorpromazine in chronic patients and open administration in schizophrenics with acute symptomatology","volume":"36","author":"Psaras","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"suppl1","key":"10.1002\/14651858.CD001719.pub3-BIB39|cit39","first-page":"159","article-title":"Comparison of risperidone and dopamine selective inhibitors in acutely exacerbated schizophrenic patients","volume":"11","author":"Saito","year":"2008","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB40|cit40","first-page":"38","article-title":"Clinical study comparing 2 different therapeutic regimens (morning vs evening administration) of bromperidol in the treatment of schizophrenia","volume":"15","author":"Scapicchio","year":"1993","journal-title":"Giornale di Neuropsicofarmacologia"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB41|cit41","first-page":"39","article-title":"Bromperidol decanoate in the residual phase of schizophrenia","volume":"37","author":"Smeraldi","year":"1996","journal-title":"Minerva Psichiatrica"},{"key":"10.1002\/14651858.CD001719.pub3-BIB42|cit42","first-page":"67","article-title":"A double-blind comparative study of bromperidol versus haloperidol in schizophrenic patients","volume":"8","author":"Spina","year":"1992","journal-title":"New Trends in Experimental and Clinical Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB43|cit43","series-title":"14th CINP Congress. Florence, Italy","article-title":"Follow-up of nine schizophrenic patients treated during 52 weeks with bromperidol decanoate","author":"Suarez Richards"},{"key":"10.1002\/14651858.CD001719.pub3-BIB44|cit44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007691-199706000-00003","article-title":"Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine","volume":"19","author":"Suzuki","year":"1997","journal-title":"Theraputic Drug Monitoring"},{"key":"10.1002\/14651858.CD001719.pub3-BIB46|cit45","first-page":"155","article-title":"Effects and side-effects of bromperidol in comparison with other antipsychotic drugs","volume":"78","author":"Woggon","year":"1978","journal-title":"Acta Psychiatrica Belgica"},{"key":"10.1002\/14651858.CD001719.pub3-BIB45|cit46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000468337","article-title":"Double-blind comparison of bromperidol and perphenazine","volume":"13","author":"Woggon","year":"1978","journal-title":"International Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB47|cit47","first-page":"236","article-title":"A single-blind comparison of bromperidol and sulpiride in hospitalized schizophrenics","volume":"93","author":"Yamagami","year":"1993","journal-title":"Acta Psychiatrica Belgica"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub3-BIB48|cit48","first-page":"4-5, 27","article-title":"Health education of families of schizophrenic patients: the impact of emotional disorder [translated by Google Translate]","volume":"7","author":"Zhao","year":"2008","journal-title":"Modern Clinical Nursing"},{"key":"10.1002\/14651858.CD001719.pub3-BIB49|cit49","series-title":"Symposium Espo. Feb 1, 1985","article-title":"Pharmacokinetics of oral and depot neuroleptics - clinical relevance","author":"Aaes-Jorgensen","year":"1985"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB50|cit50","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001718.pub2","article-title":"Depot fluspirilene for schizophrenia","author":"Abhijnhan","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001719.pub3-BIB51|cit51","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1192\/bjp.179.4.290","article-title":"Systematic meta-review of depot antipsychotic drugs for people with schizophrenia","volume":"179","author":"Adams","year":"2001","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001719.pub3-BIB53|cit53","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB54|cit54","volume-title":"The Scale for the Assessment of Positive Symptoms (SAPS)","author":"Andreasen","year":"1984"},{"issue":"6","key":"10.1002\/14651858.CD001719.pub3-BIB55|cit55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.2165\/00002018-199410060-00005","article-title":"Long term depot antipsychotics. A risk benefit assessment","volume":"10","author":"Barnes","year":"1994","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD001719.pub3-BIB56|cit56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001719.pub3-BIB57|cit57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub3-BIB58|cit58","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD001719.pub3-BIB59|cit59","volume-title":"Cochrane Reviewers' Handbook 4.20 [updated March 2003, available in Cochrane Library]","author":"Clarke","year":"2003"},{"key":"10.1002\/14651858.CD001719.pub3-BIB60|cit60","volume-title":"The Neuropsychology of Schizophrenia","author":"David","year":"1994"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB61|cit61","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001717.pub2","article-title":"Depot fluphenazine decanoate and enanthate for schizophrenia","author":"David","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub3-BIB62|cit62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003495-199447050-00004","article-title":"Depot antipsychotic drugs. Place in therapy","volume":"47","author":"Davis","year":"1994","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001719.pub3-BIB63|cit63","series-title":"Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape town","article-title":"Issues in the selection for meta-analyses of binary data","author":"Deeks","year":"2000"},{"key":"10.1002\/14651858.CD001719.pub3-BIB64|cit64","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD001719.pub3-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD001719.pub3-BIB66|cit66","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB67|cit67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB68|cit68","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1192\/bjp.195.52.s29","article-title":"Second-generation antipsychotic long-acting injections: systematic review","volume":"52","author":"Fleischhacker","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB69|cit69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB70|cit70","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB71|cit71","first-page":"124","article-title":"ECDEU Assessment manual for psychopharmacology","volume-title":"DHEW publication No (ADM)","author":"Guy","year":"1976"},{"issue":"4","key":"10.1002\/14651858.CD001719.pub3-BIB72|cit72","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.euroneuro.2010.01.001","article-title":"How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?","volume":"20","author":"Hamann","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB73|cit73","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD001719.pub3-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.4088\/JCP.v67n1216","article-title":"Attitudes of psychiatrists toward antipsychotic depot medication","volume":"67","author":"Heres","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub3-BIB75|cit75","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB76|cit76","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001719.pub3-BIB77|cit77","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org."},{"key":"10.1002\/14651858.CD001719.pub3-BIB78|cit78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0920-9964(97)85354-6","article-title":"The 100-year epidemiology of schizophrenia","volume":"28","author":"Jablensky","year":"1997","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001719.pub3-BIB79|cit79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/schbul\/19.2.287","article-title":"Psychopharmacologic treatment of schizophrenia","volume":"19","author":"Kane","year":"1993","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD001719.pub3-BIB80|cit80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0924-977X(97)00045-X","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia","volume":"8","author":"Kane","year":"1998","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB81|cit81","article-title":"Positive and negative syndrome scale (PANSS) manual","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD001719.pub3-BIB82|cit82","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD001719.pub3-BIB83|cit83","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD001719.pub3-BIB84|cit84","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artifact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1-3","key":"10.1002\/14651858.CD001719.pub3-BIB85|cit85","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia - a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD001719.pub3-BIB86|cit86","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD001719.pub3-BIB87|cit87","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001719.pub3-BIB88|cit88","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the Quality of Reports Parallel-Group Randomized Trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD001719.pub3-BIB89|cit89","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","article-title":"Schizophrenia","volume":"363","author":"Mueser","year":"2004","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001719.pub3-BIB90|cit90","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"10","key":"10.1002\/14651858.CD001719.pub3-BIB91|cit91","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1177\/0269881109104882","article-title":"Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years","volume":"24","author":"Patel","year":"2010","journal-title":"Journal of Psychopharmacology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB92|cit92","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1994.03520020051014","article-title":"Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals","volume":"272","author":"Schulz","year":"1994","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD001719.pub3-BIB93|cit93","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jclinepi.2010.02.005","article-title":"CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials","volume":"63","author":"Schulz","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD001719.pub3-BIB94|cit94","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/9780470712184.ch12","article-title":"Chapter 12: Interpreting results and drawing conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2008"},{"key":"10.1002\/14651858.CD001719.pub3-BIB95|cit95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0895-4356(94)00141-C","article-title":"Cost-effectiveness comparisons using 'real world' randomized trials: the case of new antidepressant drugs","volume":"48","author":"Simon","year":"1995","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub3-BIB96|cit96","first-page":"177","article-title":"Conversion of bromperidol to reduced bromperidol in human liver","volume":"5","author":"Someya","year":"1991","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD001719.pub3-BIB97|cit97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub3-BIB98|cit98","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1176\/appi.ps.56.3.283","article-title":"Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice","volume":"56","author":"West","year":"2005","journal-title":"Psychiatric Services"},{"issue":"7","key":"10.1002\/14651858.CD001719.pub3-BIB99|cit99","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD001719.pub3-BIB100|cit100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001719.pub2","article-title":"Depot bromperidol decanoate for schizophrenia","author":"Adams","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001719.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2012,11,14]],"date-time":"2012-11-14T00:00:00Z","timestamp":1352851200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001719.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:04:37Z","timestamp":1628528677000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001719.pub3"}},"subtitle":[],"editor":[{"given":"Marianna","family":"Purgato","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,7]]},"references-count":100,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001719.pub3","relation":{},"subject":[],"published":{"date-parts":[[2011,9,7]]}}}